查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1767761

結核病診斷市場：產業分析、規模、佔有率、成長、趨勢和預測（2025-2032）

Tuberculosis Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 177 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現

  • 結核病診斷市場規模：24億美元（2025年）
  • 預計市場價值：35億美元（2032年）
  • 全球市場成長率：5.5%（2025年至2032年的複合年成長率）

結核病診斷市場 - 報告範圍

結核病是一種嚴重影響全球健康問題的重大感染疾病，結核病診斷在結核病的檢測和管理中發揮著至關重要的作用。這些診斷工具涵蓋從傳統的塗片顯微鏡檢查到能夠快速且準確地檢測結核桿菌和抗藥性模式的先進分子檢測。結核病診斷市場服務於醫院、診斷實驗室、診所和照護現場機構等各種醫療機構，並提供多樣化的檢測組合，例如基於培養的方法、核酸增幅檢查(NAAT)、結核菌素皮膚試驗、干擾素γ釋放試驗 (IGRA) 和X光檢測。推動市場成長的因素包括全球持續的結核病負擔、對早期發現和疾病控制的持續投入，以及提高檢測準確性和周轉時間的技術進步。

市場成長動力

全球結核病診斷市場受多種因素驅動，例如持續的高結核病發病率，尤其是在醫療基礎設施低度開發的發展中地區。世界衛生組織的「終結結核病策略」等日益興起的全球計劃強調早期診斷和有效治療，這推動了對創新診斷解決方案的需求。快速分子診斷和自動化平台開發等技術進步正在提高結核病的檢出率，並促進抗藥性分析，從而實現更好的病例管理和疫情控制。此外，就地檢驗的日益普及，擴大了及時獲得結核病診斷的機會，尤其是在資源匱乏的地區，這進一步推動了市場擴張。

市場限制

儘管成長前景光明，結核病診斷市場仍面臨諸多挑戰，例如先進診斷檢測的高昂成本、低收入地區檢測基礎設施的匱乏，以及與結核病相關的社會污名化阻礙了及時檢測和診斷。複雜的監管要求和冗長的新產品核准流程也構成了市場准入和商業化的障礙。此外，某些檢測方法（尤其是在檢測潛伏性結核病方面）的診斷準確性存在差異，以及區分結核病與其他呼吸道感染疾病的持續挑戰，也給臨床決策帶來了障礙，從而影響了市場的成長。

市場機會

結核病診斷市場蘊藏著巨大的成長機會，這得益於新型分子技術、數位醫療工具的整合以及日益加強的公私合作，旨在改善結核病的檢測和治療效果。對能夠同時檢測結核病和其他呼吸道感染疾病的多疾病檢測平台的日益關注，正在提升診斷投資的商業性可行性。此外，國際衛生組織和各國政府不斷增加的資金投入，正在支持開發和部署針對高負擔地區、經濟實惠、快速便捷且方便用戶使用的結核病診斷方法。策略夥伴關係、研發投入以及創新診斷產品（例如基於次世代定序的檢測方法和可攜式核酸擴增檢測 (NAAT) 設備）的推出，對於抓住這些機會並在不斷發展的結核病診斷領域保持市場領先地位至關重要。

本報告研究了全球結核病診斷市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 任務
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考慮

  • 產品採用分析
  • 價值鏈分析
  • 監管情景
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

4. 全球結核病診斷市場展望

  • 主要亮點
    • 市場規模及年成長
    • 絕對的商機
  • 市場規模分析及預測
    • 市場規模表現分析（2019-2024）
    • 市場規模分析與預測（2025-2032）
  • 全球結核病診斷市場展望：檢測類型
    • 簡介/主要發現
    • 歷史市場規模分析：依測試類型（2019-2024）
    • 按測試類型分類的市場規模分析和預測（2025-2032）
      • 核酸檢測
      • 塗片顯微鏡檢查
      • 放射線檢查
    • 市場吸引力分析：測試類型
  • 全球結核病診斷市場展望：最終用戶
    • 簡介/主要發現
    • 按最終用戶分類的市場規模績效分析（2019-2024 年）
    • 最終用戶的市場規模分析與預測（2025-2032）
      • 醫院和診所
      • 診斷中心
      • 其他
    • 市場吸引力分析：最終用戶

5. 全球結核病診斷市場（按地區）展望

  • 主要亮點
  • 市場規模績效分析：按地區（2019-2024）
  • 各地區市場規模分析及預測（2025-2032）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美結核病診斷市場展望

7. 歐洲結核病診斷市場展望

8. 東亞結核病診斷市場展望

9. 南亞和大洋洲結核病診斷市場展望

10. 拉丁美洲結核病診斷市場展望

11.中東和非洲結核病診斷市場展望

第12章競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：按市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
    • 其他

第13章 附錄

簡介目錄
Product Code: PMRREP34779

Persistence Market Research has recently released a comprehensive report on the worldwide market for tuberculosis diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global tuberculosis diagnostics market from 2025 to 2032.

Key Insights:

  • Tuberculosis Diagnostics Market Size (2025E): USD 2.4 Billion
  • Projected Market Value (2032F): USD 3.5 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Tuberculosis Diagnostics Market - Report Scope:

Tuberculosis diagnostics play a critical role in the detection and management of tuberculosis (TB), a major infectious disease with significant global health implications. These diagnostic tools range from traditional smear microscopy to advanced molecular assays that offer rapid and precise detection of Mycobacterium tuberculosis and drug resistance patterns. The tuberculosis diagnostics market serves various healthcare settings, including hospitals, diagnostic laboratories, clinics, and point-of-care facilities, offering a diverse portfolio of tests such as culture-based methods, nucleic acid amplification tests (NAATs), tuberculin skin tests, interferon-gamma release assays (IGRAs), and radiographic examinations. Market growth is driven by the persistent global burden of tuberculosis, rising initiatives for early detection and disease control, and technological advancements improving test accuracy and turnaround times.

Market Growth Drivers:

The global tuberculosis diagnostics market is propelled by several key factors, including the sustained high incidence of tuberculosis, especially in developing regions with inadequate healthcare infrastructure. Growing global initiatives, such as the WHO's End TB Strategy, emphasize early diagnosis and effective treatment, fueling the demand for innovative diagnostic solutions. Technological advancements, including the development of rapid molecular diagnostics and automated platforms, enhance detection rates and facilitate drug-resistance profiling, enabling better patient management and outbreak control. Moreover, the increasing adoption of point-of-care testing solutions expands access to timely TB diagnosis, particularly in resource-limited settings, further driving market expansion.

Market Restraints:

Despite promising growth prospects, the tuberculosis diagnostics market faces challenges related to high costs of advanced diagnostic tests, limited laboratory infrastructure in low-income regions, and social stigma associated with TB, which can hinder timely testing and diagnosis. Complex regulatory requirements and lengthy approval processes for new diagnostic products also pose barriers for market entry and commercialization. Additionally, the variability in diagnostic accuracy of certain tests, particularly in latent TB detection, and the ongoing challenge of differentiating TB from other respiratory infections create hurdles in clinical decision-making, impacting market growth.

Market Opportunities:

The tuberculosis diagnostics market presents significant growth opportunities driven by emerging molecular technologies, integration of digital health tools, and rising public-private collaborations to improve TB detection and treatment outcomes. The increasing focus on multi-disease testing platforms that can detect TB alongside other respiratory infections enhances the commercial viability of diagnostic investments. Furthermore, rising funding from global health organizations and governments supports the development and deployment of affordable, rapid, and user-friendly TB diagnostics tailored for high-burden regions. Strategic partnerships, investments in research and development, and the launch of innovative diagnostic products, such as next-generation sequencing-based assays and portable NAAT devices, are essential to capitalize on these opportunities and sustain market leadership in the evolving TB diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the tuberculosis diagnostics market globally?
  • Which diagnostic methods and applications are fueling TB testing adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the tuberculosis diagnostics market?
  • Who are the key players contributing to the tuberculosis diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global tuberculosis diagnostics market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop advanced diagnostic solutions, including rapid molecular assays, automated testing systems, and portable diagnostic devices, addressing the diverse needs of high-burden regions and resource-limited settings. Partnerships with governments, non-governmental organizations, and global health agencies facilitate market access and promote adoption of novel TB diagnostics. Moreover, emphasis on cost-effective solutions, decentralized testing, and digital integration fosters market growth and supports public health efforts to reduce TB incidence and mortality rates worldwide.

Key Companies Profiled:

  • Abbott
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • BD
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Cepheid
  • DiaSorin S.p.A.
  • Hain Lifescience GmbH
  • Oxford Immunotec
  • Others

Tuberculosis Diagnostics Market Research Segmentation:

The tuberculosis diagnostics market encompasses a diverse range of tests, technologies, applications, and end-user segments, addressing various patient populations and clinical needs.

By Test Type

  • Nucleic Acid Testing
  • SMEAR Microscopy
  • Radiography Tests

By End User

  • Hospitals & Clinics
  • Diagnostics Centres
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Tuberculosis Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Value Chain Analysis
  • 3.3. Regulatory Scenario
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Tuberculosis Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Tuberculosis Diagnostics Market Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Nucleic Acid Testing
      • 4.3.3.2. SMEAR Microscopy
      • 4.3.3.3. Radiography Tests
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Tuberculosis Diagnostics Market Outlook: End User
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.4.3. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.4.3.1. Hospitals & Clinics
      • 4.4.3.2. Diagnostics Centres
      • 4.4.3.3. Others
    • 4.4.4. Market Attractiveness Analysis: End User

5. Global Tuberculosis Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Tuberculosis Diagnostics Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By End User
  • 6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Nucleic Acid Testing
    • 6.4.2. SMEAR Microscopy
    • 6.4.3. Radiography Tests
  • 6.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Diagnostics Centres
    • 6.5.3. Others
  • 6.6. Market Attractiveness Analysis

7. Europe Tuberculosis Diagnostics Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By End User
  • 7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Nucleic Acid Testing
    • 7.4.2. SMEAR Microscopy
    • 7.4.3. Radiography Tests
  • 7.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Diagnostics Centres
    • 7.5.3. Others
  • 7.6. Market Attractiveness Analysis

8. East Asia Tuberculosis Diagnostics Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By End User
  • 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Nucleic Acid Testing
    • 8.4.2. SMEAR Microscopy
    • 8.4.3. Radiography Tests
  • 8.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Diagnostics Centres
    • 8.5.3. Others
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Tuberculosis Diagnostics Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By End User
  • 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Nucleic Acid Testing
    • 9.4.2. SMEAR Microscopy
    • 9.4.3. Radiography Tests
  • 9.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Diagnostics Centres
    • 9.5.3. Others
  • 9.6. Market Attractiveness Analysis

10. Latin America Tuberculosis Diagnostics Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By End User
  • 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Nucleic Acid Testing
    • 10.4.2. SMEAR Microscopy
    • 10.4.3. Radiography Tests
  • 10.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Diagnostics Centres
    • 10.5.3. Others
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Tuberculosis Diagnostics Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By End User
  • 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Nucleic Acid Testing
    • 11.4.2. SMEAR Microscopy
    • 11.4.3. Radiography Tests
  • 11.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.5.1. Hospitals & Clinics
    • 11.5.2. Diagnostics Centres
    • 11.5.3. Others
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. QIAGEN
    • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.4. BD
    • 12.3.5. F. Hoffmann-La Roche AG
    • 12.3.6. Hologic, Inc.
    • 12.3.7. Cepheid
    • 12.3.8. DiaSorin S.p.A.
    • 12.3.9. Hain Lifescience GmbH
    • 12.3.10. Oxford Immunotec
    • 12.3.11. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations